Super High-Flux - High Volume Dialysis in Sepsis-Induced Acute Renal Failure
Launched by AUSTIN HEALTH · Jun 5, 2006
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND AND RATIONALE
The combination of acute renal failure (ARF) and sepsis is associated with a very high morbidity and mortality (1). Accordingly, there have many attempts to develop better treatments for this condition.
Much clinical and molecular biology research suggests that septic shock occurs because of the uncontrolled immune system's response to infection (2-13). This response involves the production of several substances (so called "humoral mediators"), which enter the blood stream and, at different times in the course of the patients' illness, cause either severe inflamma...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients who fulfil the consensus criteria for sepsis (21) and recently proposed criteria for severe ARF (1) are eligible for the study.
- Exclusion Criteria:
- • Patients under 18 years of age.
- • Patients who are pregnant or breastfeeding
- • Patients with a known allergy to polyamide
- • Patients expected to die within 24 hours
- • Patients in whom there are limitations on the intensity of therapy
About Austin Health
Austin Health is a leading healthcare organization based in Victoria, Australia, dedicated to providing high-quality patient care and advancing medical research. As a prominent clinical trial sponsor, Austin Health focuses on innovative therapeutic solutions and the development of evidence-based treatments across multiple disciplines, including oncology, cardiology, and neurology. With a commitment to ethical standards and patient safety, Austin Health collaborates with a network of researchers and institutions to facilitate cutting-edge clinical trials, aiming to enhance health outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Melbourne, Victoria, Australia
Melbourne, Victoria, Australia
Patients applied
Trial Officials
Rinaldo Bellomo, MD, FRACP
Principal Investigator
Austin Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials